Biotech

All Articles

Zephyrm looks for Hong Kong IPO to money phase 3 tissue treatment tests

.Zephyrm Bioscience is actually gusting toward the Hong Kong stock market, declaring (PDF) for an IP...

Frazier Life Sciences gathers $630M for tiny, mid-cap biotechs

.Frazier Everyday life Sciences has actually sourced an additionally $630 thousand for its own fund ...

GigaGen amasses approximately $135M BARDA dollars to beat botox

.Antitoxin enthusiast GigaGen, a subsidiary of Spanish biopharma Grifols, is increase its specialist...

GPCR agency Septerna apply for IPO on durability of preclinical information

.Septerna is about to figure out exactly how a biotech without "any type of meaningful scientific da...

Kurma closes first $154M loot for largest biotech fund yet

.European VC company Kurma Partners has introduced its own most up-to-date biotech fund, with 140 mi...

Prothena advertises one officer while yet another leaves-- Chutes &amp Ladders

.Welcome to this week's Chutes &amp Ladders, our summary of significant management hirings, firings ...

Editas cashes in on Vertex Cas9 licensing legal rights for $57M

.Against the backdrop of a Cas9 license war that rejects to perish, Editas Medication is actually mo...

Ultragenyx changes gene therapy application to dial up effectiveness

.A minority of people taking Ultragenyx Drug's Wilson condition genetics treatment UX701 have actual...

Biopharma cutback rate maintains in Q3: Fierce Biotech review

.As summer heat counts on cool down winds, hopes that this year will bring prevalent market alleviat...

J &amp J loses phase 2 dengue candidate in most current change from vaccinations

.Johnson &amp Johnson's deprioritization of its infectious illness pipeline has actually professed a...